Top Markets
#1 Akedo Akedo +55.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +47.96%
#4 Velvet Velvet +38.39%
#5 Black Phoenix Black Phoenix +34.09%
#6 Cross Cross +24.27%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.20%
#8 QANplatform QANplatform +14.54%
#9 Perle Perle +13.89%
#10 Bitway Bitway +13.56%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVXA
Rank in Stocks #38531
Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc... Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc operates as a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market innovative therapies for various female sexual dysfunctions. Its primary drug candidate, BP-101, is being developed as a medical treatment for premenopausal women diagnosed with hypoactive sexual desire disorder. This compound is presently in Phase II clinical investigation in Australia and New Zealand, and has progressed to Phase III clinical trials within Russia. Beyond its core pharmaceutical work, the company also participates in mineral exploration and offers supplementary support services. The organization, originally incorporated as Ovoca Gold plc, rebranded to Ovoca Bio plc in July 2018.
Share Price
$0.01142111
Last synced: 2025-03-21
Market Cap
$930.66K
Change (1 day)
0.18%
Change (1 year)
0.00%
Country
IE
Trade Ovoca Bio plc (OVXA)

Category

Healthcare
Revenue for Ovoca Bio plc (OVXA)
Revenue in Aug 2026 TTM: 0
According to Ovoca Bio plc latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Ovoca Bio plc from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE